Prostate Cancer Foundation Release: Novel Prostate Nanomedicine Delivers High Drug Concentration Directly and Safely to Tumors in Phase I Trials
Published: Apr 05, 2012
SANTA MONICA, Calif.--(BUSINESS WIRE)--Nanomedicine research at the David H. Koch Institute for Integrative Cancer Research at MIT funded by a $5 million grant from the Prostate Cancer Foundation (PCF) has delivered the first nanomedicine shown to successfully target prostate cancer cells and deliver docetaxel chemotherapy in high concentrations in Phase I clinical trials. Docetaxel is used in prostate cancer patients who have failed hormone therapy and is currently delivered via infusion which floods the body and affects both cancerous and healthy cells. By using targeted nanoparticles to deliver the therapeutic, healthy cells are widely spared from undesired side effects of treatment.